Skip to main content

Search

Reset all filters
731 Result(s)
Sort by

SIRPα Cancer Immunology Research

SIRPα Cancer Immunology Research

Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Martin Stefanic

Martin Stefanic

Martin Stefanic, Patient Safety Therapeutic Area Head for Oncology, discusses his move to Patient Safety.
COVID-19

COVID-19

As a research-driven company, we are part of the collective effort in fighting COVID-19. Learn more about our ongoing engagement in the fight against COVID-19
RE-LY-trial-publication-10-year-anniversary

RE-LY-trial-publication-10-year-anniversary

Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers
Sabine Reinig

Sabine Reinig

For Sabine, who leads Boehringer Ingelheim’s global people strategy, continuous development is the essence of a successful career. Clear aspirations and openness to new opportunities are her key ingredients.
Animal Health Collaboration with Novozymes

Animal Health Collaboration with Novozymes

Boehringer Ingelheim Animal Health and Novozymes today announced a strategic collaboration to develop and commercialize probiotics for global poultry production. Boehringer Ingelheim will market and distribute Novozymes’ FloraMax® probiotic product f
Interview with Michael Schmelmer

Interview with Michael Schmelmer

"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors
Women in STEM 2022

Women in STEM 2022

Meet three of Boehringer Ingelheim's female scientists and learn why and how women are making a difference in STEM.
Fredrik Gruenenfelder

Fredrik Gruenenfelder

, Lead Risk Management Physician, talks about his career journey, from veterinarian to playing a key role in keeping patients safe.
digital_leader_award_2020

digital_leader_award_2020

Boehringer Ingelheim wins first place in the "STRATEGY" category of the Digital Leader Award
Biotherapeutics Discovery

Biotherapeutics Discovery

We are applying our deep understanding of disease biology to design a diverse range of novel modalities that are the foundation for life-changing biotherapeutics for patients.
Spesolimab Phase II data

Spesolimab Phase II data

New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
EC_approval_nintedanib_ILD_PF

EC_approval_nintedanib_ILD_PF

European Commission approves nintedanib for the treatment of patients with other chronic fibrosing ILDs with a progressive phenotype beyond IPF
Vienna

Vienna

Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.